CHICAGO—Preemptive screening for cytochrome P450 2D6 (CYP2D6) mutations could optimize the efficacy of supportive care medications given to patients with cancer, given that many of these drugs are metabolized by CYP2D6 and response to these medications varies depending on the genetic variant, according to a study by investigators from North Carolina.
Supportive care medications “are prescribed based on symptom burden, but response is variable, possibly due to [